Product Description
Clopidogrel is used alone or with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a stroke, heart attack, or severe chest pain. This includes people who have percutaneous coronary intervention (PCI; angioplasty; a type of heart surgery) that may involve inserting coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) or who have coronary artery bypass grafting (CABG; a type of heart surgery). Clopidogrel is also used to prevent serious or life-threatening problems with the heart and blood vessels in people who have peripheral arterial disease (poor circulation in the blood vessels that supply blood to the legs). Clopidogrel is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke. (Sourced from: https://medlineplus.gov/druginfo/meds/a601040.html)
Mechanisms of Action: P2Y12 Antagonist,GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Mexico, Norway, Pakistan, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Ischemic Stroke|Myocardial Infarction|Scleroderma, Diffuse|Scleroderma, General|Scleroderma, Systemic|Thrombosis
Phase 2: Ischemic Attack, Transient
Phase 1: Acute Coronary Syndrome|Angina, Stable|Angina, Unstable|Blood Platelet Disorders|Chronic Pain|Coronary Disease|Healthy Volunteers|Peripheral Arterial Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PSSIT | P3 |
Recruiting |
Scleroderma, Systemic|Scleroderma, General|Scleroderma, Diffuse |
2030-06-01 |
|
| ANDES | P3 |
Active, not recruiting |
Thrombosis|Ischemic Stroke |
2026-07-18 |
|
| U54AT008909 | P1 |
Recruiting |
Blood Platelet Disorders|Chronic Pain |
2025-08-31 |
|
| TADCLOT | P3 |
Recruiting |
Thrombosis|Myocardial Infarction |
2024-11-15 |